News and Trends 27 Oct 2016
UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle
After a promising kick off, Novartis is raising doubts about the future of its CAR-T program with its decision to dissolve and reintegrate the cell and gene therapy division into its immuno-oncology effort. Yes, you read that correctly: despite exciting progress by Novartis’s CAR-T therapy program, the company is reportedly disbanding the cell and gene therapy […]